D-Pharm Ltd. (TASE: DPRM) today reported positive results in an ECG heart monitoring trial for its DP-b99 drug for ischemic stroke treatment. The trial was carried out on 32 healthy patients at a medical center in South Africa, in parallel to a Phase III clinical trial there for DP-b99.
Following the announcement of the results the company's share price rose 4% but then fell back. In afternoon trading D-Pharm's share price was up 1.7% to NIS 19.44. Clal Biotechnology Industries Ltd. (TASE: CBI) holds 46.6% of D-Pharm.
The results of the monitoring trial found that ECG safety was retained even when administering high dosages of DP-b99 and that there was no negative influence on the electrical activity of the heart.
D-Pharm VP, clinical development Dr. Gilad Rosenberg said, "This is an important milestone for us. Not only has the electrocardiographic safety of DP-b99 been proven as safe in clinical dosages but also the safety of higher dosages than those used until now has been proven."
The US Food and Drug Administration (FDA) approved Phase III clinical trial for DP-b99 is being conducted on 770 patients in 100 medical centers in North America, South America, Europe and South Africa, South Korea and elsewhere.
Published by Globes, Israel business news - www.globes-online.com - on August 10, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010